Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of a drug called Thymoglobulin, combined with a delayed
start of the anti-rejection drugs (10 days after liver transplant), compared to the current
approach of starting anti-rejection drugs called calcineurin inhibitors or CNI's within 2
days after the liver transplant.